Breakthrough designation AstraZeneca’s severe asthma drugThe first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after Share XBreakthrough designation AstraZeneca’s severe asthma drughttps://pharmaphorum.com/news/astrazeneca-asthma-breakthrough/
SBRI Healthcare digital projects saved NHS £30 million so farAn NHS England technology funding enterprise, the Small Business Research Initiative (SBRI) Healthcare, secured over £30 million in Share XSBRI Healthcare digital projects saved NHS £30 million so farhttps://pharmaphorum.com/digital/sbri-digital-projects-saved-nhs-30m/
GSK cuts 650 jobs in the USGlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to Share XGSK cuts 650 jobs in the UShttps://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/
Novartis sells parts of Sandoz for $1bnAfter disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo Share XNovartis sells parts of Sandoz for $1bnhttps://pharmaphorum.com/news/novartis-sells-sandoz-parts/
Sanofi to pay $25 million in bribery charges settlementFrench pharma giant Sanofi reached a civil settlement with the US Securities and Exchange Commission (SEC) and agreed Share XSanofi to pay $25 million in bribery charges settlementhttps://pharmaphorum.com/news/sanofi-pays-25-m-bribery-settlement/
Puma Biotechnology’s breast cancer drug approved in EuropePuma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines Share XPuma Biotechnology’s breast cancer drug approved in Europehttps://pharmaphorum.com/news/ec-approves-puma-breast-cancer-drug/
Abivax sets its course on colitis and Crohn’sFrench biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 Share XAbivax sets its course on colitis and Crohn’shttps://pharmaphorum.com/news/abivax-scolitis-crohns/
UK’s drug supply contingency plan for hard BrexitThe UK government has issued several documents to help businesses in planning for the eventuality of a no-deal Share XUK’s drug supply contingency plan for hard Brexithttps://pharmaphorum.com/views-analysis-market-access/hard-brexit-uk-drug-supply-contingency-plan/
Ipsen appoints new general manager for the UK & IrelandThe French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali, Share XIpsen appoints new general manager for the UK & Irelandhttps://pharmaphorum.com/news/ipsen-appoints-new-general-manager/
